NOVO
Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?
Wockhardt's Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk's Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
Weekly-once insulin jab may soon come to India
A new weekly insulin dosage by Novo Nordisk, Insulin Icodec, is on the brink of approval in India, offering potential relief for those who require daily insulin injections. The Subject Expert Committee has recommended permitting the import and sale of this innovative product, expected to revolutionise the insulin market. While further studies are required, doctors anticipate improved patient compliance with this new treatment option.
Best toys for your toddlers to keep them happy and engaged
This expertly curated article offers a treasure trove of engaging options designed to captivate your toddlers' imaginations. From playset that foster cognitive growth to cute little soft dolls that ensure comfort and joy, our selection caters to every child's unique interests. Whether you're seeking imaginative playsets or cuddly companions, our article is your ultimate resource for finding the best toys to nurture your toddler's development and ensure endless hours of joy and exploration.
Ozempic: Bengaluru is the secret ingredient behind the wonder weight loss drugs' success
Novo Nordisk's India team played a pivotal role in the success of Ozempic, a semaglutide-based drug for diabetes and weight management. The Bengaluru-based Global Business Services unit collaborated on clinical trials and biostatistics. Despite global demand, Ozempic's availability in India remains uncertain due to supply challenges, with significant hiring planned to bolster Novo Nordisk's workforce in India.
European shares close shy of record after ECB delivers first rate-cut in five years
In new forecasts, the ECB said it expected inflation to average 2.2% in 2025 - up from a previous estimate of 2.0% and meaning it was now seen holding above the central bank's 2% target well into next year. ECB President Christine Lagarde said that only one ECB Governing Council member had opposed the bank's decision to cut interest rates earlier in the day.
J&J acquires experimental skin disorder drug for $1.25 billion
NUMAB THERAPEUTICS-JOHNSON&JOHNSON/M&A (UPDATE 2, PIX)UPDATE 2-J&J acquires experimental skin disorder drug for $1.25 billion
New study warns of serious side effects from popular weight loss drugs Wegovy and Ozempic, finds they may paralyse stomach
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis, characterized by delayed stomach emptying. The study, presented at Digestive Disease Week 2024, indicates a 30% higher risk for users of these drugs. Experts emphasize the need for awareness and medical monitoring of potential gastrointestinal side effects.
Massive fire at Danish pharma giant Novo Nordisk
A massive fire broke out at a Novo Nordisk office building in Copenhagen, prompting the evacuation of all occupants. Around 100 firefighters worked to extinguish the blaze that spread from a construction site to an adjacent building. There were no injuries reported nor was there any impact on drug production.
Wegovy should be treating more than just obesity
A new analysis highlights the significant cardiovascular benefits of Novo Nordisk's obesity drug Wegovy, showing improvements regardless of weight loss amount. This challenges perceptions of GLP-1 drugs, suggesting they could be viewed more as heart or metabolic medications. Improved access and understanding are crucial, as these drugs could impact various chronic conditions like kidney disease. Acknowledging these connections could lead to more effective treatment approaches and better outcomes.
Uphill Battle: Navigating the Complexities of Diabetes Management
Managing type 2 diabetes involves crucial lifestyle changes for blood sugar control, mental health support, weight management, nutrition therapy, stress management, physical activity, and glucose regulation.
New oral diabetes + obesity drug's India sales surge 100%
India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenges and evolving disease patterns as it grows as a superpower.
KKR acquires Healthium from Apax Partners for Rs 7,000 cr
KKR acquired Healthium Medtech Ltd., a leading Indian medical devices company, from Apax Partners. The deal, valued at approximately Rs 7000 crore, involves a special purpose vehicle owned by KKR-managed funds gaining control of Healthium. Healthium, the fourth-largest surgical suture manufacturer globally, maintains a strong presence in India and abroad, with KKR aiming to leverage its expertise to further expand its reach
KKR to buy Healthium Medtech for Rs 7000 cr from Apax
Binding agreement signed; formal announcement by early next week, pips rival bidders Mankind Pharma-Chrys Cap Healthium is the largest manufacturer of surgical needles globally by volume.
Novo Nordisk owner to invest $200 million in quantum computing startups
Novo Holdings, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk, which is known for producing blockbuster obesity drug Wegovy and diabetes treatment Ozempic.
Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in India
Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife for my appearance,” says Rajput. The drugs — Wegovy and Ozempic — which have the same ingredient, semaglutide, are all the rage ever since entrepreneur Elon Musk tweeted about it.
'Wars are changing': Army Chief and CDS want Indian forces to adopt de-novo mantra for future warfare
General Anil Chauhan, Chief of Defence Staff, initiated 'Parivartan Chintan' in New Delhi, focusing on developing a joint culture for the Armed Forces. The conference aimed to generate fresh ideas for jointness and integration among the services. Discussions included modernization, procurement, training, and collaboration, with a focus on emerging technologies and national strategic issues. This initiative aligns with the Indian armed forces' transformation towards joint structures, ensuring they are "future ready." The conference highlighted the importance of jointness and integration for theatre commands and broader defence reforms.
Novo Nordisk to buy Cardior Pharma for up to $1 billion
Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies aim to improve heart function, aligning with Novo's focus on diabetes and obesity history.
Novo Nordisk owner joins the race for Healthium Medtech
Novo Holdings is the latest challenger in a hotly contested bidding process for Healthium, 99.8% owned by Apax Partners. Buyout funds KKR, Hillhouse, EQT, Blackstone and TA Associates among others have already been shortlisted after the initial rounds, ET reported on March 11. Novo Holdings' foray is expected to exacerbate competition for Healthium, which has been valued by rival bidders at Rs 6,500-7,000 crore. Due diligence for the company is underway.
AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare-disease portfolio
AstraZeneca announced its acquisition of Amolyt Pharma, a company focused on endocrine diseases, for $1.05 billion in cash. This move aims to strengthen AstraZeneca's rare diseases portfolio. Amolyt Pharma, based in France, is in the late-stage development of a therapy for hypoparathyroidism called eneboparatide.
Load More
